Lexaria Bioscience (LEXX) Institutional Ownership $0.90 +0.04 (+4.65%) As of 07/3/2025 02:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Lexaria Bioscience (NASDAQ:LEXX)CurrentInstitutional OwnershipPercentage13.06%Number ofInstitutional Buyers(last 12 months)9TotalInstitutional Inflows(last 12 months)$3.68MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$251.88K Get LEXX Insider Trade Alerts Want to know when executives and insiders are buying or selling Lexaria Bioscience stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data LEXX Institutional Buying and Selling by Quarter Lexaria Bioscience Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/16/2025Invenomic Capital Management LP549,947$940K0.0%+33.9%3.132% 4/16/2025Byrne Asset Management LLC28,905$49K0.0%+122.3%0.165% 3/17/2025Wealth Enhancement Advisory Services LLC28,873$61K0.0%+108.9%0.164% 2/17/2025Invenomic Capital Management LP410,731$863K0.0%-13.7%2.340% 2/13/2025Raymond James Financial Inc.60,640$127K0.0%N/A0.346% 2/12/2025Geode Capital Management LLC166,679$350K0.0%+10.8%0.950% 2/7/2025HighTower Advisors LLC21,023$44K0.0%+61.4%0.120% 2/6/2025Raymond James Financial Inc.60,640$127K0.0%N/A0.346% 1/28/2025Byrne Asset Management LLC13,000$27K0.0%+132.1%0.074% 11/16/2024Geode Capital Management LLC150,391$459K0.0%+31.0%0.951% Get the Latest News and Ratings for LEXX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter. 11/15/2024XTX Topco Ltd18,626$57K0.0%+47.8%0.118% 11/15/2024Invenomic Capital Management LP475,773$1.45M0.1%-7.4%3.007% 11/15/2024HighTower Advisors LLC13,023$40K0.0%N/A0.082% 8/15/2024Armistice Capital LLC1,020,000$2.84M0.0%N/A7.916% 8/9/2024Renaissance Technologies LLC22,800$63K0.0%N/A0.177% 5/16/2024Invenomic Capital Management LP473,265$1.72M0.1%-35.3%3.672% 4/9/2024Welch Group LLC24,000$87K0.0%N/A0.194% 2/14/2024Invenomic Capital Management LP731,981$915K0.0%-4.2%7.011% 2/8/2024Cowen AND Company LLC256,327$320K0.1%N/A2.455% 11/15/2023Armistice Capital LLC889,272$889K0.0%N/A10.992% 8/14/2023Invenomic Capital Management LP766,573$560K0.0%+62.0%9.476% 8/8/2022Merit Financial Group LLC21,267$63K0.0%N/A0.357% 2/11/2022Invenomic Capital Management LP359,113$1.45M0.3%+1.9%6.034% 11/15/2021MD Financial Management Inc.407,687$2.55M0.1%+15,078.2%7.988% 8/16/2021Invenomic Capital Management LP317,110$2.22M0.5%+7.1%6.213% 8/13/2021Renaissance Technologies LLC17,200$120K0.0%N/A0.337% 8/13/2021Geode Capital Management LLC50,385$352K0.0%N/A0.987% 8/13/2021Vanguard Group Inc.25,976$182K0.0%N/A0.509% 5/21/2021Citadel Advisors LLC14,915$84K0.0%N/A0.292% 5/18/2021Citadel Advisors LLC14,915$84K0.0%N/A0.292% (Data available from 1/1/2016 forward) LEXX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of LEXX shares? During the previous two years, 11 institutional investors and hedge funds held shares of Lexaria Bioscience. The most heavily invested institutionals were Armistice Capital LLC ($2.84M), Invenomic Capital Management LP ($940K), Geode Capital Management LLC ($350K), Cowen AND Company LLC ($320K), Raymond James Financial Inc. ($127K), Welch Group LLC ($87K), and Renaissance Technologies LLC ($63K).Learn more on Lexaria Bioscience's institutional investors. What percentage of Lexaria Bioscience's stock is owned by institutional investors? 13.06% of Lexaria Bioscience's stock is owned by institutional investors. Learn more on LEXX's institutional investor holdings. Which institutional investors have been buying Lexaria Bioscience's stock? Of the 11 institutional investors that purchased Lexaria Bioscience's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Armistice Capital LLC ($1.91M), Invenomic Capital Management LP ($432.69K), Cowen AND Company LLC ($256.33K), Raymond James Financial Inc. ($121.28K), Geode Capital Management LLC ($51.90K), Welch Group LLC ($24K), and Byrne Asset Management LLC ($23.31K). How much institutional buying is happening at Lexaria Bioscience? Institutional investors have bought a total of 1,420,594 shares in the last 24 months. This purchase volume represents approximately $3.68M in transactions. Which of Lexaria Bioscience's major shareholders have been selling company stock? The following institutional investors have sold Lexaria Bioscience stock in the last 24 months: Invenomic Capital Management LP ($102.84K). How much institutional selling is happening at Lexaria Bioscience? Institutional investors have sold a total of 102,842 shares in the last 24 months. This volume of shares sold represents approximately $251.88K in transactions. Related Companies RPTX Institutional Ownership CNTX Institutional Ownership NRXP Institutional Ownership GANX Institutional Ownership IRD Institutional Ownership VTGN Institutional Ownership GNTA Institutional Ownership SNTI Institutional Ownership CUE Institutional Ownership PMVP Institutional Ownership This page (NASDAQ:LEXX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
